Modification of casein micelles by aptamers for targeted drug delivery purposes - biophysical characterization of formulations by size exclusion chromatography

Modification of casein micelles by aptamers for targeted drug delivery purposes - biophysical characterization of formulations by size exclusion chromatography

Section reference: 
Year:
2022

Overall rating

Scientific work
67%
Design
67%
Discussion interaction
67%
UserScientific workDesignDiscussion interaction
Mgr. Lukáš Ihnacik 100%100%100%
ISBN: 978-80-972360-8-3

Modification of casein micelles by aptamers for targeted drug delivery purposes - biophysical characterization of formulations by size exclusion chromatography

Isabel Králová1 , Zuzana Garaiová , Milan Zvarík , Martina Velísková , Tibor Hianik
1 Department of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovakia
iz.kralova@gmail.com

Caseins belong to the group of milk proteins, which gain a lot of interest as a potential biopolymeric platform for creating an affordable and effective drug delivery vehicle [1]. The structural and physicochemical properties of caseins allow their self-assembly into structures called micelles with the possibility to encapsulate hydrophobic bioactive agents and pharmaceuticals including anticancer drugs [2]. Effective transport of loaded material should be targeted – drugs being delivered to the site of their desired therapeutic effect. This can be performed by modification of drug carriers by DNA aptamers [3]. DNA aptamers are short single-stranded oligonucleotides that bind to specific molecular targets due to their three-dimensional structure. In this work, we used sgc8c DNA aptamer that specifically binds to protein tyrosine kinase 7 (PTK7), which is highly expressed in the membranes of the leukemic cells [4].

We have focused on the preparation of β-casein micelles and their modification with fluorescently labeled (Atto542) sgc8c aptamer conjugated by a cholesteryl-TEG linker (Chol-sgc8c-Atto542). The micelles were made from β-casein (2 mg/ml) in Na-phosphate buffer (10 mmol/l, pH 7) in the presence of CaCl2 (10 mmol/l) or without CaCl2 under constant stirring for 1.5 h at 25 °C, followed by filtration through a 0.2 μm pore size filter. The filtered micelles were modified with aptamers (2 μmol/l) under constant stirring for 2 h at laboratory temperature. The prepared formulations were analyzed by fluorescence measurements using size exclusion chromatography (SEC-HPLC) on a 30 nm size pore column. The fluorescent signal coming from the internal fluorescence of β-casein (λex = 295 nm, λem = 343 nm) and from the Atto542- fluorescence of aptamer (λex = 540 nm, λem = 565 nm) were obtained. The fluorescence peak of β-casein eluted at 3.4 min decreased for the complexed sample of β-casein + Chol-sgc8c-Atto542, and the fluorescence signal from the aptamer was partly shifted to this region, indicating a successful modification. Similar results were observed for the complexed sample in the presence of CaCl2. In both cases, aptamers being not coeluted – signal at later retention times was also observed, indicating the presence of unbound Chol-sgc8c-Atto542, too.

The obtained results can serve for optimization of the experimental protocol and as a base for further studies of the casein micelles modified by aptamers as a targeted drug delivery platform in cancer treatment.

Thanks: 

This work has been financially supported by Science Grant Agency VEGA, projects No. 1/0756/20 and 1/0419/20; by Agency for PromotionResearch and Development, project No. SK-PL-18-0080 and SK-BY-RD-19-0019; by KEGA, project No. 041UK-4/2020 and by NAWA International Academic Partnership Programme EUROPARTNER.

Sources: 

[1] Jyotsana R. Madan, et al. Formulation and In Vitro Evaluation of Casein Nanoparticles as Carrier for Celecoxib. Advanced pharmaceutical bulletin. 2020. DOI:10.34172/apb.2020.049
[2] Mo Li, et al. Bovine beta-casein micelles as delivery systems for hydrophobic flavonoids. Food Hydrocolloids. 2019. DOI:10.1016/j.foodhyd.2019.06.005
[3] Zhaoying Fu, et al. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. International Journal of Molecular Sciences. 2020. DOI:10.3390/ijms21239123
[4] Alexandra Poturnayová, et al. DNA Aptamers in the Detection of Leukemia Cells by the Thickness Shear Mode Acoustics Method. Chemphyschem: a European journal of chemical physics and physical chemistry. 2019. DOI:10.1002/cphc.20180112

Discussion

Veľmi pekná práca, ďakujeme. Chcela by som sa spýtať na výhody kazeínových miciel ako nosičov liečiv a či nemôže byť problémom pomerne vysoké percento intolerancie na potraviny s obsahom kazeínu v populácii (?)

Nice piece of work, thank you. I would like to ask about the advantages of casein micelles as drug carriers, and about whether the relatively high percentage of  casein-linked allergies encountered in the population could be an obstacle (?)

iwa

Thank you very much for your question.

Casein is an inexpensive, readily available, non-toxic, and highly stable protein. Other advantages of casein include biocompatibility, biodegradability, and amphiphilic nature. Due to its structural and physicochemical properties, casein can be used in drug delivery systems. These properties include binding of ions and small molecules, exceptional surface-active and stabilizing properties, excellent emulsification, and self-assembly properties together with superb gelation and water binding capacities. The substantial association property of casein is favorable for the nanoencapsulation processes [1].

In our study, we used β-casein, which accounts for approximately 30 % of the total protein of cows’ milk and can occur in one of two major genetic variants: A1 and A2. According to various studies, e.g. [2, 3], the A1 variant of β-casein can potentially cause intolerance (stomach pain and other gastrointestinal symptoms). After the consumption of milk containing only the A2 variant, most of the patients did not experience the same problems as after consuming the A1 variant. By preparing micelles from the A2 variant of β-casein, we could enable a more accessible form of the drug delivery system.

 

[1] Madan, J. R., Ansari, I. N., Dua, K., & Awasthi, R. (2020). Formulation and In Vitro Evaluation of Casein Nanoparticles as Carrier for Celecoxib. Advanced pharmaceutical bulletin, 10 (3), 408–417. https://doi.org/10.34172/apb.2020.049

[2] Pal, S., Woodford, K., Kukuljan, S., & Ho, S. (2015). Milk Intolerance, Beta-Casein and Lactose. Nutrients, 7 (9), 7285–7297. https://doi.org/10.3390/nu7095339

[3] He, M., Sun, J., Jiang, Z. Q., & Yang, Y. X. (2017). Effects of cow's milk beta-casein variants on symptoms of milk intolerance in Chinese adults: a multicentre, randomised controlled study. Nutrition journal, 16 (1), 72. https://doi.org/10.1186/s12937-017-0275-0

 

 

Thank you for the explanation.

I wish you good luck in your future endeavours.

iwa